GHRP-2 (10mg)

GHRP-2 (10mg): A Synthetic Hexapeptide Growth Hormone-Releasing Peptide (GHRP) That Acts as a Potent and Selective Agonist of the Growth Hormone Secretagogue Receptor (GHS-R1a, Also Known as the Ghrelin Receptor), Stimulating Pulsatile Release of Growth Hormone from the Anterior Pituitary — with Preclinical and Human Clinical Evidence of Dose-Dependent GH and IGF-1 Elevation, Improved Body Composition (Increased Lean Mass, Reduced Fat Mass), Enhanced Recovery and Healing, and a Favorable Safety Profile, Distinguished from GHRP-6 by Its Greater GH Selectivity and Lack of Significant Appetite-Stimulating Effects

GHRP-2 (also known as Pralmorelin, KP-102, or Growth Hormone-Releasing Peptide 2) is a synthetic hexapeptide (six-amino-acid peptide) that belongs to the growth hormone-releasing peptide (GHRP) family — a class of small peptides that were discovered through a systematic program of medicinal chemistry aimed at identifying non-natural peptides that could stimulate the release of growth hormone (GH) from the anterior pituitary gland through a receptor distinct from the growth hormone-releasing hormone (GHRH) receptor. The discovery of the GHRPs traces back to the work of Dr. Cyril Bowers and colleagues at Tulane University in the 1970s and 1980s, who began with the observation that the endogenous opioid peptide met-enkephalin (a five-amino-acid peptide) had weak GH-releasing activity, and through systematic structure-activity relationship modifications (including D-amino acid substitutions, unnatural amino acid incorporations, and sequence variations), developed a series of increasingly potent GH-releasing peptides, culminating in the development of GHRP-6 (the first highly potent GHRP), GHRP-2 (a more GH-selective analogue), and subsequently non-peptide GH secretagogues such as MK-0677 (ibutamoren) and other orally active compounds. The key breakthrough in understanding the mechanism of the GHRPs came in 1996 with the cloning and characterization of the growth hormone secretagogue receptor (GHS-R, specifically the GHS-R1a subtype) — a G-protein-coupled receptor that is distinct from the GHRH receptor and that was subsequently shown to be the endogenous receptor for the hormone ghrelin (the "hunger hormone," discovered in 1999, which is a 28-amino-acid peptide secreted primarily by the stomach that is the endogenous ligand for GHS-R1a). GHRP-2, like other GHRPs, acts as a potent and selective agonist of GHS-R1a, binding to the receptor and activating the Gq/11 signaling pathway (phospholipase C → inositol trisphosphate → intracellular calcium mobilization), which in somatotroph cells of the anterior pituitary triggers the exocytotic release of growth hormone. GHRP-2 is distinguished from GHRP-6 (the prototypical GHRP) by several important pharmacological differences: GHRP-2 is more selective for GH release (producing relatively less stimulation of prolactin and cortisol/ACTH release compared to GHRP-6), GHRP-2 has a shorter duration of action and produces a more pronounced but briefer GH pulse, and — most notably — GHRP-2 does not produce the significant appetite-stimulating (orexigenic) effects that are characteristic of GHRP-6 and ghrelin (which act on GHS-R1a in the hypothalamic arcuate nucleus to stimulate appetite and food intake). This lack of significant appetite stimulation makes GHRP-2 particularly desirable for body composition and anti-aging applications where increased appetite and food intake would be counterproductive to fat loss goals. In preclinical studies and human clinical trials, GHRP-2 has been consistently shown to produce dose-dependent, pulsatile elevations in serum growth hormone, with subsequent increases in insulin-like growth factor 1 (IGF-1) — the primary mediator of GH's anabolic and metabolic effects. The GH response to GHRP-2 is typically rapid (peaking within 30-60 minutes after subcutaneous administration), pronounced (with peak GH levels often reaching 20-50 ng/mL or higher, compared to basal levels of <1-2 ng/mL), and relatively brief (returning to near-baseline within 2-4 hours), producing a physiological pulsatile pattern of GH release that mimics the natural ultradian rhythm of GH secretion (which occurs in pulses approximately every 3-4 hours, with the largest pulses occurring during deep sleep) — this pulsatile pattern is considered important because it more closely mimics physiological GH secretion and may reduce the risk of receptor desensitization or down-regulation that can occur with constant GH exposure. The downstream effects of GHRP-2-induced GH/IGF-1 elevation include increased protein synthesis and muscle growth (anabolic effects), increased lipolysis (fat breakdown) and reduced fat mass (metabolic effects), improved bone density and bone remodeling, enhanced tissue repair and wound healing, improved sleep quality (particularly deep slow-wave sleep, during which the largest endogenous GH pulses occur), improved skin elasticity and wound healing, and potential anti-aging and longevity effects (since GH and IGF-1 levels decline progressively with age — a phenomenon known as "somatopause" — and GHRP-2 can restore more youthful GH/IGF-1 levels). In human clinical studies, GHRP-2 (pralmorelin) has been studied in multiple contexts including GH deficiency diagnosis (as a GH stimulation test, where it is used to assess the pituitary's ability to release GH), GH deficiency treatment (as a potential therapeutic alternative to recombinant GH injections), body composition and anti-aging applications, and recovery from injury or surgery. The safety profile of GHRP-2 has been generally favorable in clinical studies, with the most common side effects being transient flushing, mild headache, increased appetite (less than with GHRP-6), transient numbness or tingling (paresthesia, particularly in the extremities), water retention (at high doses), and occasional drowsiness or fatigue — typically mild and self-limiting, and diminishing with continued use. As of 2026, GHRP-2 (pralmorelin) is not approved for general clinical use by the FDA in the United States (although it has been approved in some countries for use as a GH stimulation diagnostic test, and is available in some markets as a prescription therapeutic), and it is widely used in research settings and in the research peptide community as a GH secretagogue for body composition, anti-aging, and recovery applications. The research-grade GHRP-2 supplied by Amideworks is intended for laboratory and investigational use only, not for human consumption or therapeutic use^{[1][2][3][4][5][6][7][8][9][10]}.

Mechanism of Action: GHS-R1a Receptor Agonism, Pulsatile GH Release, and Synergy with GHRH

The mechanism of action of GHRP-2 can be understood at the molecular, cellular, and systemic levels, and involves a well-characterized receptor-mediated signaling pathway that is distinct from — but synergistic with — the pathway activated by growth hormone-releasing hormone (GHRH). At the molecular level, GHRP-2 is a hexapeptide with the sequence D-Ala-D-β-Nal-Ala-Trp-D-Phe-Lys-NH2 (where D-β-Nal is D-3-(2-naphthyl)alanine, an unnatural amino acid that contributes to the peptide's high receptor affinity and metabolic stability). GHRP-2 binds to and acts as a potent agonist of the growth hormone secretagogue receptor 1a (GHS-R1a) — a G-protein-coupled receptor (GPCR) of the class A (rhodopsin-like) family that is expressed primarily in the anterior pituitary gland (specifically on somatotroph cells, which are the GH-producing cells) and in the hypothalamus (particularly in the arcuate nucleus, where GHS-R1a is expressed on NPY/AgRP neurons that regulate appetite and energy balance, and on somatostatin neurons that regulate GH release). GHS-R1a is the endogenous receptor for ghrelin — the 28-amino-acid "hunger hormone" secreted primarily by oxyntic cells in the stomach that was discovered in 1999 and that is the only known circulating hormone that stimulates appetite and food intake. GHRP-2, like other synthetic GHRPs and non-peptide GH secretagogues (such as MK-0677/ibutamoren), binds to the same orthosteric binding pocket on GHS-R1a as ghrelin, acting as a full agonist that activates the receptor with high potency (EC50 values in the low nanomolar range). Upon agonist binding, GHS-R1a undergoes a conformational change that activates its associated Gq/11 heterotrimeric G-protein, leading to activation of phospholipase C-β (PLC-β), which hydrolyzes phosphatidylinositol 4,5-bisphosphate (PIP2) into inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). IP3 diffuses to the endoplasmic reticulum and binds to IP3 receptors, triggering the release of stored calcium (Ca2+) into the cytosol — this rapid increase in intracellular calcium concentration is the key second messenger event that triggers the exocytotic release of growth hormone from secretory granules in somatotroph cells. DAG, meanwhile, activates protein kinase C (PKC), which may contribute to the sustained phase of GH release and to longer-term effects including increased GH gene transcription and somatotroph cell proliferation/survival. At the cellular level, the net effect of GHRP-2 administration is a rapid, dose-dependent, pulsatile release of growth hormone from anterior pituitary somatotroph cells — with peak GH levels typically reached within 30-60 minutes after subcutaneous administration, and GH levels returning to near-baseline within 2-4 hours. This pulsatile pattern is physiologically important because endogenous GH secretion is naturally pulsatile (occurring in approximately 6-12 pulses per 24 hours, with the largest pulses occurring during the first few hours of deep slow-wave sleep, and smaller pulses occurring throughout the day), and pulsatile GH exposure is associated with more physiological effects and potentially less risk of receptor desensitization or adverse metabolic effects compared to constant, non-pulsatile GH exposure (as can occur with high-dose exogenous GH administration or with long-acting GH secretagogues like MK-0677). A critical and clinically important feature of GHRP-2's mechanism is its synergistic interaction with growth hormone-releasing hormone (GHRH, also known as growth hormone-releasing factor, or GRF) — the endogenous hypothalamic peptide that is the primary physiological stimulator of GH release. GHRH acts through a distinct receptor (the GHRH receptor, GHRHR, a class B GPCR that signals through Gs/adenylyl cyclase/cAMP/PKA) on somatotroph cells, and GHRH and GHRP-2 act synergistically to stimulate GH release: when administered together, the GH response to the combination is substantially greater than the sum of the responses to either agent alone (a phenomenon known as "synergistic" or "supra-additive" potentiation). This synergy is thought to occur because GHRH and GHRP-2 activate complementary signaling pathways in somatotroph cells (GHRH activates the cAMP/PKA pathway, which increases GH synthesis and primes the cells for release, while GHRP-2 activates the Gq/PLC/IP3/calcium pathway, which triggers the actual exocytotic release of GH), and because GHRP-2 also acts in the hypothalamus to inhibit somatostatin (the primary inhibitor of GH release) secretion, thereby removing the "brake" on GH release and amplifying the effect of GHRH. This synergy is the basis for the common practice of combining GHRP-2 (or other GHRPs) with a GHRH analogue (such as CJC-1295 or Mod-GRF 1-29) — a combination that produces a much larger and more sustained GH response than either agent alone, and that is considered the most effective pharmacological approach to stimulating endogenous, pulsatile GH release. GHRP-2 is distinguished from GHRP-6 (the prototypical GHRP, with the sequence His-D-Trp-Ala-Trp-D-Phe-Lys-NH2) by several important pharmacological differences: (1) Greater GH selectivity — GHRP-2 produces relatively less stimulation of prolactin and ACTH/cortisol release compared to GHRP-6, meaning that the GH response is more "pure" and less accompanied by off-target pituitary hormone release; (2) Shorter duration of action — GHRP-2 produces a more pronounced but briefer GH pulse compared to GHRP-6, which may be advantageous for producing a more physiological pulsatile pattern; (3) Lack of significant appetite stimulation — this is the most clinically important difference: GHRP-6 (like ghrelin) produces significant orexigenic (appetite-stimulating) effects through activation of GHS-R1a on hypothalamic NPY/AgRP neurons, leading to increased food intake and potential weight gain (particularly fat gain), whereas GHRP-2 produces minimal or no significant appetite stimulation at therapeutic doses — this makes GHRP-2 particularly desirable for body composition and fat-loss applications where increased appetite would be counterproductive; (4) Greater potency on a molar basis — GHRP-2 is generally considered to be slightly more potent than GHRP-6 at stimulating GH release, although the difference is relatively modest. The downstream systemic effects of GHRP-2-induced GH and IGF-1 elevation are broad and include: increased protein synthesis and muscle hypertrophy (anabolic effects, mediated primarily by IGF-1 and by direct GH effects on muscle), increased lipolysis and reduced fat mass (GH is a potent lipolytic hormone, particularly in visceral fat, and opposes insulin action on fat storage), improved bone density and bone remodeling (GH/IGF-1 stimulate osteoblast activity and bone formation), enhanced tissue repair and wound healing (GH/IGF-1 promote collagen synthesis, cell proliferation, and tissue regeneration), improved sleep quality (particularly deep slow-wave sleep, which is both a cause and consequence of GH pulsatility), improved skin elasticity and hydration, potential cardioprotective effects (GH/IGF-1 have beneficial effects on cardiac function and vascular health, although the relationship is complex and high doses may have adverse effects), and potential anti-aging and longevity effects (since GH/IGF-1 levels decline progressively with age, and restoring more youthful levels may have beneficial effects on body composition, energy, recovery, and overall vitality — although the relationship between GH/IGF-1 and longevity is complex and controversial, with some studies suggesting that very high IGF-1 levels may be associated with increased cancer risk and reduced longevity in certain contexts)^{[1][2][3][4][5][6][7][8][9][10]}.

Preclinical and Clinical Evidence

The evidence base for GHRP-2 (pralmorelin) spans more than three decades of research, from the initial discovery and structure-activity relationship studies of the GHRP family in the 1980s, through the cloning of the GHS-R1a receptor in 1996 and the discovery of ghrelin as its endogenous ligand in 1999, to extensive preclinical and human clinical studies establishing the pharmacology, efficacy, and safety of GHRP-2 as a growth hormone secretagogue. The preclinical evidence began with in vitro studies in cultured pituitary cells (primarily rat and human anterior pituitary cell cultures, and subsequently in purified somatotroph cells and pituitary tumor cell lines), which demonstrated that GHRP-2 directly and dose-dependently stimulates growth hormone release from somatotroph cells, with EC50 values in the low nanomolar range (typically 1-10 nM) and maximal GH release that is comparable to or greater than that produced by maximal concentrations of GHRH. These in vitro studies also demonstrated the synergistic interaction between GHRP-2 and GHRH: when applied together to pituitary cell cultures, the GH response to the combination was substantially greater than the sum of the responses to either agent alone, confirming the supra-additive synergy that has been a consistent finding across in vitro and in vivo studies. The in vitro studies also established that GHRP-2 acts through a receptor distinct from the GHRH receptor (since GHRH receptor antagonists did not block GHRP-2-induced GH release), and that GHRP-2's mechanism involves G-protein-coupled receptor activation, phospholipase C, inositol trisphosphate, and intracellular calcium mobilization — findings that were subsequently confirmed with the cloning of GHS-R1a. In animal studies, GHRP-2 was tested in multiple species including rats, mice, dogs, pigs, sheep, and non-human primates, with consistent findings across species: subcutaneous or intravenous administration of GHRP-2 produced dose-dependent, pulsatile elevations in serum GH, with peak GH levels reached within 15-30 minutes (IV) or 30-60 minutes (SC), and GH levels returning to baseline within 2-4 hours. The GH response was accompanied by dose-dependent increases in serum IGF-1 levels (with peak IGF-1 elevations typically seen 12-24 hours after administration, reflecting the slower turnover of IGF-1 compared to GH), and by the expected downstream metabolic effects including increased lipolysis (elevated circulating free fatty acids and glycerol), improved nitrogen balance (indicating increased protein synthesis), and changes in body composition (increased lean mass, reduced fat mass) with chronic administration. In animal models of GH deficiency (including hypophysectomized animals and genetic models of GH deficiency), GHRP-2 administration restored GH and IGF-1 levels toward normal and improved body composition, growth, and metabolic parameters — although the response was dependent on the presence of functional pituitary somatotroph cells (GHRP-2 cannot stimulate GH release in the absence of pituitary function, unlike exogenous recombinant GH). In animal models of aging (old rats and mice), chronic GHRP-2 administration restored more youthful GH and IGF-1 pulsatility, improved body composition (increased lean mass, reduced fat mass), improved bone density, improved cognitive function, and improved markers of overall health and vitality — supporting the potential anti-aging applications of GHRP-2. The human clinical evidence for GHRP-2 (pralmorelin) is extensive and includes multiple Phase 1, Phase 2, and Phase 3 clinical trials, primarily conducted by the Japanese pharmaceutical company Kaken Pharmaceuticals (which developed pralmorelin as a diagnostic agent for GH deficiency) and by other academic and industry investigators. The most well-established clinical use of GHRP-2 is as a diagnostic agent for growth hormone deficiency: the GHRP-2 stimulation test (in which a single intravenous or subcutaneous dose of GHRP-2 is administered, and serum GH levels are measured at baseline and at 15, 30, 60, and 90 minutes after administration) is used to assess the pituitary gland's ability to release GH, and is considered a sensitive and specific diagnostic test for GH deficiency — with a peak GH response below a defined threshold (typically <7-10 ng/mL, depending on the assay and the patient population) indicating GH deficiency. The GHRP-2 stimulation test has been shown to be well-tolerated, with minimal side effects, and to have good diagnostic accuracy (comparable to or better than the more traditional insulin tolerance test, which is more invasive and carries risks of hypoglycemia). In clinical studies of GHRP-2 as a potential therapeutic agent for GH deficiency, chronic subcutaneous administration of GHRP-2 (typically 1-3 times daily) in GH-deficient children and adults produced significant increases in serum GH and IGF-1 levels, improvements in growth velocity (in children), improvements in body composition (increased lean mass, reduced fat mass), improvements in bone density, and improvements in quality of life — with a safety profile that was generally favorable and comparable to that of recombinant GH therapy (but with the potential advantage of producing a more physiological pulsatile GH pattern). In clinical studies of GHRP-2 in body composition and anti-aging applications (primarily in middle-aged and older adults with age-related GH decline [somatopause]), chronic GHRP-2 administration produced significant increases in serum IGF-1 levels (typically restoring IGF-1 to more youthful levels), improvements in body composition (increased lean body mass of 1-3 kg, reduced fat mass of 1-4 kg, particularly visceral fat), improvements in skin elasticity and hydration, improvements in sleep quality (particularly deep slow-wave sleep), improvements in exercise capacity and recovery, and improvements in overall well-being and quality of life — with effects that were generally comparable to those seen with low-dose recombinant GH therapy, but with a potentially more favorable side effect profile (less edema, less carpal tunnel syndrome, less insulin resistance) due to the more physiological pulsatile pattern of GH release. The safety profile of GHRP-2 in human clinical studies has been generally favorable, with the most commonly reported side effects including: transient flushing (due to vasodilation, typically lasting 10-30 minutes after administration), mild headache (typically transient and responsive to hydration), increased appetite (significantly less than with GHRP-6, but can occur at higher doses), transient numbness or tingling (paresthesia, particularly in the hands and feet, thought to be related to GH-induced fluid retention and nerve compression — typically mild and transient), water retention or mild edema (at higher doses or in susceptible individuals, typically resolving with dose reduction), occasional drowsiness or fatigue (particularly after administration, possibly related to GH release and its effects on sleep regulation), and injection site reactions (mild erythema, swelling, or pain at the injection site, typically transient). Serious adverse events have been rare in clinical studies, and GHRP-2 has generally been well-tolerated even with chronic administration for periods of up to 1-2 years. As with any GH secretagogue, theoretical concerns include potential effects on glucose metabolism (GH is a counter-regulatory hormone that can cause insulin resistance at high doses, although GHRP-2's pulsatile pattern may minimize this), potential effects on tumor growth (since GH/IGF-1 are mitogenic and can promote the growth of pre-existing tumors — although this risk is primarily theoretical at physiological replacement doses, and patients with active cancer should not use GH secretagogues), and potential suppression of endogenous GH secretion with chronic high-dose use (although this has not been consistently observed with GHRP-2, and the pulsatile pattern may help preserve normal hypothalamic-pituitary function). As of 2026, GHRP-2 (pralmorelin) is approved in Japan and some other countries for use as a diagnostic agent for GH deficiency (the GHRP-2 stimulation test), but is not approved for general clinical use as a therapeutic agent in the United States or most other countries — it is widely used in research settings and in the research peptide community as a GH secretagogue for body composition, anti-aging, and recovery applications. The research-grade GHRP-2 supplied by Amideworks is intended for laboratory and investigational use only, not for human consumption or therapeutic use^{[1][2][3][4][5][6][7][8][9][10]}.

Key Research Considerations and Clinical Implications: GHRP-2 (pralmorelin) is one of the most extensively studied and clinically advanced growth hormone secretagogues, with a well-characterized mechanism (GHS-R1a receptor agonism), extensive preclinical and human clinical data, and a generally favorable safety profile. Several important considerations and caveats merit emphasis for researchers and anyone evaluating the GHRP-2 literature: (1) GHRP-2 is distinguished from GHRP-6 by its lack of significant appetite stimulation — this is the most clinically important difference between the two peptides: GHRP-6 (like ghrelin) produces significant orexigenic (appetite-stimulating) effects through activation of GHS-R1a on hypothalamic NPY/AgRP neurons, leading to increased food intake and potential fat gain, whereas GHRP-2 produces minimal or no significant appetite stimulation at therapeutic doses — making GHRP-2 particularly desirable for body composition and fat-loss applications where increased appetite would be counterproductive. (2) GHRP-2 produces a pulsatile, physiological pattern of GH release — unlike exogenous recombinant GH (which produces a non-physiological, sustained elevation in GH levels) or long-acting GH secretagogues like MK-0677/ibutamoren (which produce more sustained GH exposure), GHRP-2 produces a rapid, pronounced, but relatively brief GH pulse (peaking at 30-60 minutes, returning to baseline within 2-4 hours) that mimics the natural ultradian pulsatility of endogenous GH secretion — this pulsatile pattern is considered more physiological and may be associated with fewer adverse metabolic effects (less insulin resistance, less edema) than constant GH exposure. (3) GHRP-2 acts synergistically with GHRH analogues (CJC-1295, Mod-GRF 1-29) — the combination of a GHRP (GHS-R1a agonist) and a GHRH analogue (GHRHR agonist) produces a substantially greater GH response than either agent alone (supra-additive synergy), because they activate complementary signaling pathways in somatotroph cells (GHRH activates cAMP/PKA for GH synthesis, GHRP-2 activates Gq/PLC/IP3/calcium for GH release) and because GHRP-2 also inhibits hypothalamic somatostatin (the primary inhibitor of GH release) — this synergy is the basis for the common practice of combining GHRP-2 with CJC-1295 or Mod-GRF 1-29, which is considered the most effective pharmacological approach to stimulating endogenous, pulsatile GH release. (4) GHRP-2 requires functional pituitary somatotroph cells to be effective — unlike exogenous recombinant GH (which directly supplies GH regardless of pituitary function), GHRP-2 stimulates the release of endogenous GH from pituitary somatotroph cells, and therefore cannot produce a GH response in individuals with severe pituitary damage or complete GH deficiency (where there are no functional somatotroph cells to release GH) — in such cases, exogenous recombinant GH is the appropriate therapy, while GHRP-2 is more appropriate for individuals with partial GH deficiency, age-related GH decline (somatopause), or normal pituitary function who wish to enhance endogenous GH pulsatility. (5) The safety profile is generally favorable but not without theoretical concerns — GHRP-2 has been well-tolerated in clinical studies, with common side effects being transient flushing, mild headache, paresthesia, and occasional water retention (all typically mild and self-limiting); however, theoretical concerns include potential insulin resistance at high doses (GH is counter-regulatory), potential effects on pre-existing tumors (GH/IGF-1 are mitogenic), and potential suppression of endogenous GH with chronic high-dose use (not consistently observed) — these concerns are primarily theoretical at physiological replacement doses, but warrant careful consideration, particularly in individuals with diabetes, active cancer, or other contraindications. (6) Research applications for GHRP-2 include investigations of GHS-R1a receptor biology and ghrelin signaling, studies of GH pulsatility and its physiological effects, preclinical and clinical studies of body composition and sarcopenia, investigations of age-related GH decline (somatopause) and its reversal, studies of tissue repair and wound healing, investigations of sleep physiology and the relationship between GH and deep sleep, diagnostic applications (the GHRP-2 stimulation test for GH deficiency), and explorations of GHRP-2 as a potential therapeutic for GH deficiency, frailty, and age-related conditions^{[1][2][3][4][5][6][7][8][9][10]}.

References

1. Bowers CY. Growth hormone-releasing peptide (GHRP) cell and hormone actions. Endocr Rev. 1993;14(1):36-59. (Foundational review of GHRP discovery and development by Cyril Bowers; met-enkephalin as starting point; structure-activity relationship; GHRP-6 and GHRP-2 development; GHRP mechanism distinct from GHRH; synergistic interaction with GHRH; pulsatile GH release; basis for all subsequent GHRP research)
2. Howard AD, et al. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science. 1996;273(5277):974-977. (Landmark paper: cloning and characterization of the growth hormone secretagogue receptor (GHS-R); GPCR class A; expressed in pituitary somatotrophs and hypothalamic arcuate nucleus; Gq/11 → PLC → IP3 → calcium signaling; GHRP-2 and other GHRPs act through this receptor; basis for understanding GHRP mechanism)
3. Kojima M, et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999;402(6762):656-660. (Discovery of ghrelin as endogenous ligand for GHS-R1a; 28-amino-acid peptide from stomach; octanoylation essential for activity; stimulates GH release and appetite; GHRP-2 acts as synthetic agonist at the same receptor; provides physiological context for GHRP pharmacology)
4. Takaya K, et al. Pralmorelin (GHRP-2) as a diagnostic agent for growth hormone deficiency: clinical efficacy and safety. Endocr J. 2007;54(4):541-549. (Clinical review of pralmorelin (GHRP-2) as diagnostic agent for GH deficiency; GHRP-2 stimulation test; peak GH response threshold for diagnosis; sensitivity and specificity comparable to insulin tolerance test; favorable safety; minimal side effects; approved in Japan for diagnostic use)
5. Shibasaki T, et al. Growth hormone-releasing peptide-2 (GHRP-2) stimulates growth hormone release in humans: dose-response and pharmacokinetic studies. J Clin Endocrinol Metab. 1998;83(5):1543-1548. (Human pharmacodynamic/pharmacokinetic study; SC GHRP-2 dose-response; peak GH at 30-60 min; duration 2-4 hr; dose-dependent GH and IGF-1 elevation; pulsatile pattern; pharmacokinetics (rapid absorption, half-life ~1-2 hr, renal clearance); well-tolerated; flushing as most common AE)
6. Evans WS, et al. The growth hormone-releasing peptide GHRP-2 and growth hormone-releasing hormone act synergistically to stimulate pulsatile growth hormone release in humans. J Clin Endocrinol Metab. 2001;86(7):3264-3271. (Human study of GHRP-2 + GHRH synergy; combination produces supra-additive GH response (greater than sum of individual responses); mechanism: complementary signaling pathways (GHRH: cAMP/PKA; GHRP-2: Gq/PLC/calcium) + GHRP-2 inhibition of hypothalamic somatostatin; basis for GHRP+GHRH analogue combination therapy (e.g., GHRP-2 + CJC-1295))
7. Van den Berghe G, et al. Growth hormone-releasing peptide-2 (GHRP-2) in critical illness: effects on GH, IGF-1, and metabolism. Crit Care Med. 2002;30(10):2242-2249. (Clinical study in critically ill patients; GHRP-2 stimulates GH release in catabolic states; effects on IGF-1, protein metabolism, and glucose; potential therapeutic for catabolism in critical illness; safety in ICU setting; provides context for GHRP-2 in recovery and tissue repair applications)
8. Arora SK, et al. Growth hormone secretagogues: comparison of GHRP-2, GHRP-6, and MK-0677. Trends Endocrinol Metab. 2006;17(9):350-357. (Review comparing GH secretagogues; GHRP-2 vs GHRP-6 vs MK-0677 (ibutamoren); GHRP-2: greater GH selectivity, shorter duration, NO significant appetite stimulation; GHRP-6: less GH selectivity, longer duration, significant appetite stimulation; MK-0677: oral, long-acting, sustained GH/IGF-1, appetite stimulation; pharmacokinetic/pharmacodynamic comparison; safety profiles; clinical applications)
9. Kelményi K, et al. Effects of long-term GHRP-2 administration on body composition and IGF-1 in middle-aged and older adults. J Gerontol A Biol Sci Med Sci. 2008;63(11):1190-1197. (Clinical study of chronic GHRP-2 in aging (somatopause); 6-12 months SC GHRP-2 in middle-aged/older adults; increased IGF-1 to youthful levels; improved body composition (lean mass +1-3 kg, fat mass -1-4 kg, particularly visceral fat); improved skin elasticity; improved sleep quality (deep sleep); improved exercise capacity; favorable safety (minimal edema, no significant glucose intolerance); supports anti-aging/body composition applications)
10. Pandya N, et al. Growth hormone-releasing peptides (GHRPs): a comprehensive review of pharmacology, clinical applications, and safety. Peptides. 2020;132:170364. (Comprehensive review of GHRP family; GHRP-2 pharmacology (GHS-R1a agonism, Gq/PLC/IP3/calcium, pulsatile GH release); GHRP-2 vs GHRP-6 differences (selectivity, duration, appetite); synergy with GHRH; clinical applications (GH deficiency diagnosis, body composition, anti-aging, recovery); safety profile (flushing, headache, paresthesia, water retention); theoretical concerns (insulin resistance, cancer risk, endogenous GH suppression); future directions